Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (111)

2024

  1. Delphi consensus for the third-line treatment of metastatic colorectal cancer

    Clinical and Translational Oncology

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

  2. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

    Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 32-44

  3. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388

  4. Post-Chemoradiation Metastatic, Persistent and Resistant Nodes in Locally Advanced Rectal Cancer: Metrics and Their Impact on Long-Term Outcome

    Cancers, Vol. 15, Núm. 18

  5. Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3378-3394

  6. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  3. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494

  4. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  5. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 11, pp. 2107-2119

  6. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 2, pp. 161-170

  7. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554

  8. Indocyanine green clearance test as a predictor of chemotherapy liver toxicity and post-operative complications in patients with colorectal liver metastases

    Cirugia y Cirujanos (English Edition), Vol. 90, Núm. 3, pp. 310-318

  9. Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”

    Annals of Hepato-Biliary-Pancreatic Surgery, Vol. 26, Núm. 4, pp. 363-374

  10. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

    ESMO Open, Vol. 7, Núm. 3

  11. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer

    Critical Reviews in Oncology/Hematology, Vol. 173

  12. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades

    Annals of Hepato-Biliary-Pancreatic Surgery, Vol. 25, Núm. 2, pp. 179-191